HERMED Technische Beratungs GmbH is a consulting and service company for the economic and legally secure management of medical technology in healthcare.

HERMED Technische Beratungs GmbH

ACROBiosystems develops and supplies proteins and reagents for various applications in biomedicine, including cell and gene therapy solutions, therapeutic antibodies, and vaccine development.

ACROBiosystems

B. Braun is a medical technology company that provides a range of products and services related to healthcare.

B. Braun

Drägerwerk AG & Co. KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, system products, and other services. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as fire training facilities for firefighters. Drägerwerk AG & Co. KGaA was founded in 1889 and is headquartered in Lübeck, Germany.

Metric
Company Name	HERMED Technische Beratungs GmbH	ACROBiosystems	B. Braun	Drägerwerk AG & Co. KGaA
Symbol				DRW8
MSH ID	DE:HERMED	COM:ACROBIOSYSTEMS	COM:BBRAUN	COM:DRAEGER
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Medical Technology	Biotechnology	Medical Devices	Medical - Devices
Country	DE	US	DE	DE
Stage
Employee Count				16.48K
Website	hermed.de	acrobiosystems.com	bbraun.com	draeger.com
LinkedIn
Founders

Metric
Market Cap				979.59M
Enterprise Value
Monthly Web Traffic				522.21K
Web Traffic Growth				-0.10
Valuation
Raised Capital

Metric
Revenue				3.56B
Revenue (LTM)
Revenue (NTM)
Gross Profit				1.48B
EBITDA				359.77M
Operating Income				202.87M
Net Income				116.64M
EPS				6.22
Diluted EPS				6.22
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.44
Operating Profit Margin				0.06
EBITDA Margin				0.10
Net Profit Margin				0.03
Return on Equity				0.08
Return on Assets				0.04
Return on Capital Employed				0.08

DE:HERMED

HERMED Technische Beratungs GmbH

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				8.35
P/B Ratio				0.57
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				0.28
EV Multiple				3.47

Metric
Days Sales Outstanding				79.69
Days Payables Outstanding				38.40
Days Inventory Outstanding				138.91
Operating Cycle				226.35
Cash Conversion Cycle				188.82
Asset Turnover				1.11

Metric
Operating Cash Flow				200.34M
Free Cash Flow				128.30M
Cash Flow to Debt				0.80
Operating Cash Flow/Sales				0.07
Free Cash Flow Yield				0.13

Metric
Cash & Equivalents				287.25M
Accounts Receivable				-72.35M
Inventory				694.88M
Goodwill				328.74M
Debt to Capitalization				0.22
Debt to Assets				0.12
Current Ratio				1.83
Quick Ratio				1.17

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue				0.10
SG&A to Revenue				0.07